Achaogen, Inc. stock performance trend indicates that the stock price has rallied 72.1% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 367.43% . Looking at the past 52 week period, the stock price is up at 591.05% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Achaogen, Inc. has a positive value of 376.4 compared to overall market.Achaogen, Inc. is having a Relative Strength Index of 45.33 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Achaogen, Inc. (NASDAQ:AKAO) has tumbled 17.11% during the past week and has dropped 1.28% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 17.3%. Achaogen, Inc. (NASDAQ:AKAO) has underperformed the index by 2.4% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. Achaogen, Inc. (NASDAQ:AKAO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.68 points or 2.95% at $22.39 with 1,918,952 shares getting traded. Post opening the session at $23.27, the shares hit an intraday low of $22.0601 and an intraday high of $23.5899 and the price was in this range throughout the day. The company has a market cap of $801 million and the number of outstanding shares has been calculated to be 35,781,564 shares. The 52-week high of Achaogen, Inc. (NASDAQ:AKAO) is $27.79 and the 52-week low is $2.5875.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Stifel on Mar 15, 2017 to Buy, Raises Price Target to $ 28 from a previous price target of $27 .Company shares were Reiterated by Wedbush on Mar 6, 2017 to Outperform, Raises Price Target to $ 28 from a previous price target of $23 .Company shares were Reiterated by Needham on Mar 2, 2017 to Buy, Raises Price Target to $ 29 from a previous price target of $19 .Achaogen Inc was Initiated by Stifel on Feb 7, 2017 to Buy, Price Target of the shares are set at $27.Company shares were Reiterated by Wedbush on Feb 1, 2017 to Outperform, Raises Price Target to $ 23 from a previous price target of $19 .
Company has reported several Insider transactions to the SEC, on Mar 16, 2017, Kenneth J. Hillan (Chief Executive Officer) sold 3,079 shares at 26.58 per share price.On Feb 23, 2017, Ian Friedland (SVP, Chief Medical Officer) sold 1,026 shares at 22.76 per share price.On Feb 23, 2017, Zeryn Sarpangal (officer ) sold 439 shares at 22.76 per share price.
Achaogen Inc Last issued its quarterly earnings results on Mar 14, 2017. The company reported $-1.04 EPS for the quarter, missing the analyst consensus estimate by $ -0.55. Analyst had a consensus of $-0.49. The company had revenue of $10.73 million for the quarter, compared to analysts expectations of $13.33 million. The companys revenue was up 130.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.61 EPS.
Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.